J&J nabs new OK for IL-23 drug Tremfya; Merck KGaA spinout ups Series A tally to €20.1M
→ J&J has gotten the greenlight to add active psoriatic arthritis to Tremfya’s label. The drug “is the first and only selective IL-23 inhibitor approved for both active psoriatic arthritis and moderate to severe plaque psoriasis, as well as the only biologic approved for the treatment of psoriatic arthritis to have improvement in fatigue as measured by FACIT-F included in the U.S. Prescribing Information,” David Lee, the therapeutic head of immunology at Janssen, said in a statement.
→ Merck KGaA spinout iOnctura has expanded its Series A by €5.1 million ($5.8 million), bringing the total haul to €20.1 million ($22.9 million). 3B Future Health Fund, which is backed by Helsinn, is behind the new investment. The injection will fund the startup’s dual immune and tumor targeting therapies, including the lead program targeting PI3Kδ and a second compound blocking ATX.